WO2002083648A1 - Novel 1h-indazole compound - Google Patents
Novel 1h-indazole compound Download PDFInfo
- Publication number
- WO2002083648A1 WO2002083648A1 PCT/JP2002/003735 JP0203735W WO02083648A1 WO 2002083648 A1 WO2002083648 A1 WO 2002083648A1 JP 0203735 W JP0203735 W JP 0203735W WO 02083648 A1 WO02083648 A1 WO 02083648A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- novel
- indazole compound
- single bond
- cyclic hydrocarbon
- hydrocarbon group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Paper (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-7013494A KR20040007497A (ko) | 2001-04-16 | 2002-04-15 | 신규 1h-인다졸 화합물 |
AT02724612T ATE449763T1 (de) | 2001-04-16 | 2002-04-15 | 1h-indazolverbindungen die jnk hemmen |
US10/469,399 US6982274B2 (en) | 2001-04-16 | 2002-04-15 | 1H-indazole compound |
AU2002255263A AU2002255263B2 (en) | 2001-04-16 | 2002-04-15 | Novel 1H-indazole compound |
JP2002581404A JP4535680B2 (ja) | 2001-04-16 | 2002-04-15 | 新規1h−インダゾール化合物 |
CA002440842A CA2440842A1 (en) | 2001-04-16 | 2002-04-15 | Novel 1h-indazole compounds |
DE60234510T DE60234510D1 (de) | 2001-04-16 | 2002-04-15 | 1h-indazolverbindungen die jnk hemmen |
EP02724612A EP1380576B1 (en) | 2001-04-16 | 2002-04-15 | 1h-indazole compounds inhibiting jnk |
US11/202,234 US7541376B2 (en) | 2001-04-16 | 2005-08-12 | 1H-indazole compounds |
US12/426,818 US7776890B2 (en) | 2001-04-16 | 2009-04-20 | 1H-indazole compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001116521 | 2001-04-16 | ||
JP2001-116521 | 2001-04-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10469399 A-371-Of-International | 2002-04-15 | ||
US11/202,234 Division US7541376B2 (en) | 2001-04-16 | 2005-08-12 | 1H-indazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002083648A1 true WO2002083648A1 (en) | 2002-10-24 |
Family
ID=18967246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/003735 WO2002083648A1 (en) | 2001-04-16 | 2002-04-15 | Novel 1h-indazole compound |
Country Status (10)
Country | Link |
---|---|
US (3) | US6982274B2 (ja) |
EP (1) | EP1380576B1 (ja) |
JP (1) | JP4535680B2 (ja) |
KR (1) | KR20040007497A (ja) |
CN (1) | CN1300116C (ja) |
AT (1) | ATE449763T1 (ja) |
AU (1) | AU2002255263B2 (ja) |
CA (1) | CA2440842A1 (ja) |
DE (1) | DE60234510D1 (ja) |
WO (1) | WO2002083648A1 (ja) |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003064397A1 (en) * | 2002-01-25 | 2003-08-07 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
WO2003068754A1 (en) * | 2002-02-13 | 2003-08-21 | Astrazeneca Ab | Therapeutic substituted indazole derivatives |
WO2003101968A1 (fr) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Compose de pyrazole et composition medicinale le contenant |
WO2004031159A1 (en) * | 2002-09-25 | 2004-04-15 | Wyeth | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (er) ligands and their use in the treatment of inflammatory diseases |
WO2004089366A1 (en) * | 2003-04-10 | 2004-10-21 | Pfizer Japan, Inc. | Bicyclic compounds as nr2b receptor antagonists |
WO2004113303A1 (en) * | 2003-06-26 | 2004-12-29 | Astrazeneca Ab | INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF |
JP2005075834A (ja) * | 2003-09-03 | 2005-03-24 | Carlsbad Technology Inc | 神経変性疾患の処置 |
WO2005035516A1 (ja) * | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
WO2005066136A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
JP2005533004A (ja) * | 2002-03-11 | 2005-11-04 | アベンティス・ファーマ・ソシエテ・アノニム | 抗癌活性を有する置換インダゾール |
EP1633740A2 (en) * | 2003-06-19 | 2006-03-15 | SmithKline Beecham Corporation | Chemical compounds |
JP2006512143A (ja) * | 2002-12-31 | 2006-04-13 | セルジーン・コーポレーション | 薬剤被覆ステントおよびその使用方法 |
US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
JP2007511618A (ja) * | 2003-11-19 | 2007-05-10 | シグナル ファーマシューティカルズ,エルエルシー | インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法 |
WO2008001886A1 (fr) | 2006-06-30 | 2008-01-03 | Kyowa Hakko Kirin Co., Ltd. | Inhibiteur d'aurora |
WO2008001885A1 (fr) | 2006-06-30 | 2008-01-03 | Kyowa Hakko Kirin Co., Ltd. | INHIBITEUR DE KINASE Abl |
JP2008508304A (ja) * | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 縮合環ヘテロ環キナーゼ調節因子 |
US7378532B2 (en) | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
US7390797B2 (en) | 2002-02-28 | 2008-06-24 | Eisai Co., Ltd. | Fused indazole compounds |
JP2008530028A (ja) * | 2005-02-24 | 2008-08-07 | テバ ファーマシューティカル インダストリーズ リミティド | リネゾリッド中間体の調製方法 |
WO2008111441A1 (ja) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
DE102007032739A1 (de) | 2007-07-13 | 2009-01-15 | Merck Patent Gmbh | Chinazolinamidderivate |
DE102007041116A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-Dihydro-isoindolderivate |
US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
JP2009541377A (ja) * | 2006-07-01 | 2009-11-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hsp90誘発疾患を治療するためのインダゾール誘導体 |
US7652135B2 (en) | 2003-09-23 | 2010-01-26 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
DE102008061214A1 (de) | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
US7803824B2 (en) | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
EP2248521A1 (en) | 2004-10-29 | 2010-11-10 | Alcon, Inc. | Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases |
JP2010536846A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 |
JP2011515414A (ja) * | 2008-03-20 | 2011-05-19 | アボット・ラボラトリーズ | Trpv1アンタゴニストである中枢神経系薬剤を作製する方法 |
DE102009054302A1 (de) | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
DE102010046837A1 (de) | 2010-09-29 | 2012-03-29 | Merck Patent Gmbh | Phenylchinazolinderivate |
JP2012521429A (ja) * | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のp2x3受容体アンタゴニスト |
US8268994B2 (en) | 2004-07-27 | 2012-09-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9416126B2 (en) | 2013-03-04 | 2016-08-16 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9440952B2 (en) | 2013-03-04 | 2016-09-13 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9688654B2 (en) | 2013-03-04 | 2017-06-27 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
JP2020516632A (ja) * | 2017-04-11 | 2020-06-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | フッ素置換されたインダゾール化合物及びその使用 |
US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
JP2022508128A (ja) * | 2018-11-15 | 2022-01-19 | エイチケー イノ.エヌ コーポレーション | タンパク質キナーゼ阻害剤としての新規化合物およびそれを含む薬学的組成物 |
CN113999211A (zh) * | 2021-11-23 | 2022-02-01 | 郑州大学 | 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物 |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11524968B2 (en) | 2017-10-18 | 2022-12-13 | Hk Inno.N Corporation | Heterocyclic compound as a protein kinase inhibitor |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
US12071428B2 (en) | 2024-02-22 | 2024-08-27 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
CN1300116C (zh) * | 2001-04-16 | 2007-02-14 | 卫材株式会社 | 1h-吲唑化合物 |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
EA010165B1 (ru) * | 2003-07-30 | 2008-06-30 | Киова Хакко Когио Ко., Лтд. | Производные индазола |
AU2004260759B2 (en) * | 2003-07-30 | 2010-04-22 | Kyowa Hakko Kirin Co., Ltd. | Protein kinase inhibitors |
US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
ES2298853T3 (es) | 2003-12-22 | 2008-05-16 | Basilea Pharmaceutica Ag | Aroilfuranos y aroiltiofenos apropiados para el tratamiento del cancer. |
BRPI0508107A (pt) * | 2004-02-27 | 2007-07-17 | Hoffmann La Roche | derivados de indazol e composições farmacêuticas contendo os mesmos |
GB0409080D0 (en) * | 2004-04-23 | 2004-05-26 | Biofocus Discovery Ltd | Compounds which interact with protein kinases |
EP1847532B1 (en) * | 2005-01-27 | 2013-06-05 | Kyowa Hakko Kirin Co., Ltd. | Igf-1r inhibitor |
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CA2642762A1 (en) * | 2006-02-16 | 2007-08-30 | Schering Corporation | Pyrrolidine derivatives as erk inhibitors |
MX2008012658A (es) * | 2006-03-31 | 2008-12-16 | Schering Corp | Inhibidores de cinasa. |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
SI2007756T1 (sl) | 2006-04-07 | 2015-11-30 | Vertex Pharmaceuticals Incorporated | Modulatorji prenašalcev z atp-vezavno kaseto |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
WO2008061109A2 (en) * | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
WO2008082487A2 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
CA2672960A1 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
JP2010535245A (ja) | 2007-07-31 | 2010-11-18 | バーンハム インスティテュート フォー メディカル リサーチ | キナーゼ阻害剤としての二座化合物 |
WO2009105500A1 (en) * | 2008-02-21 | 2009-08-27 | Schering Corporation | Compounds that are erk inhibitors |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
SG10201913594UA (en) | 2010-04-22 | 2020-02-27 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
WO2011163330A1 (en) * | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
WO2012015932A2 (en) * | 2010-07-27 | 2012-02-02 | Protexer, Inc. | Shoe cover removal apparatus |
EP2613782B1 (en) * | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
MX347889B (es) | 2010-09-03 | 2017-05-17 | Forma Tm Llc * | Compuestos y composiciones novedosos para la inhibición de nampt. |
CA2819373A1 (en) * | 2010-12-09 | 2012-06-14 | Amgen Inc. | Bicyclic compounds as pim inhibitors |
EP2654748B1 (en) * | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
JP2014510105A (ja) | 2011-03-22 | 2014-04-24 | アムジエン・インコーポレーテツド | Pim阻害剤としてのアゾール化合物 |
US9580390B2 (en) | 2011-10-12 | 2017-02-28 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
KR101511771B1 (ko) * | 2011-12-20 | 2015-04-14 | 주식회사 엘지생명과학 | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 |
CA2869730A1 (en) | 2012-04-25 | 2013-10-31 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
US8980934B2 (en) | 2012-06-22 | 2015-03-17 | University Health Network | Kinase inhibitors and method of treating cancer with same |
WO2014010732A1 (ja) | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
WO2014056083A1 (en) * | 2012-10-12 | 2014-04-17 | University Health Network | Kinase inhibitors and method of treating cancer with same |
WO2014142255A1 (ja) | 2013-03-14 | 2014-09-18 | 武田薬品工業株式会社 | 複素環化合物 |
US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015002230A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | アミド化合物 |
DK3027605T3 (en) | 2013-07-31 | 2018-01-22 | Council Scient Ind Res | Hitherto UNKNOWN INDAZOL RELATIONS AND PROCEDURES FOR PREPARING IT |
WO2015154169A1 (en) | 2014-04-09 | 2015-10-15 | The University Of British Columbia | Binding function3 (bf3) site compounds as therapeutics and methods for their use |
LT3424534T (lt) | 2014-04-15 | 2021-11-10 | Vertex Pharmaceuticals Incorporated | Farmacinės kompozicijos, skirtos gydyti ligas, kurių atsiradimui tarpininkauja cistinės fibrozės transmembraninio laidumo reguliatorius |
CN105061316B (zh) * | 2015-07-17 | 2017-12-22 | 苏州大学 | 稠环类化合物、制备方法和用途 |
WO2017028314A1 (en) * | 2015-08-20 | 2017-02-23 | Changzhou Jiekai Pharmatech Co., Ltd. | Pyrazolo fused heterocyclic compounds as erk inhibitors |
KR102484810B1 (ko) * | 2016-05-25 | 2023-01-05 | (주)아모레퍼시픽 | 피부 미백용 조성물 |
JP6803410B2 (ja) * | 2017-02-14 | 2020-12-23 | 富士フイルム株式会社 | インダゾール化合物の製造方法およびインダゾール化合物 |
WO2018234353A1 (en) * | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE |
WO2018234354A1 (en) * | 2017-06-20 | 2018-12-27 | Grünenthal GmbH | NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS |
WO2021050672A1 (en) * | 2019-09-11 | 2021-03-18 | Ohio State Innovation Foundation | Kinase inhibitors for the treatment of neurodegenerative diseases |
US20210094935A1 (en) * | 2019-10-01 | 2021-04-01 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2024124279A1 (en) * | 2022-12-16 | 2024-06-20 | Certa Therapeutics Pty Ltd | Heterocyclic compounds and uses thereof |
Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1266763B (de) * | 1965-07-27 | 1968-04-25 | Kalle Ag | Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten |
JPS51125281A (en) * | 1975-01-15 | 1976-11-01 | Chugai Pharmaceut Co Ltd | A process for preparing indazole derivatives |
JPS52122366A (en) * | 1976-04-02 | 1977-10-14 | Chugai Pharmaceut Co Ltd | Indazole derivatives |
EP0023633A1 (en) * | 1979-07-16 | 1981-02-11 | Chugai Seiyaku Kabushiki Kaisha | Pyrazoloindazole derivatives and process for preparing the same and pharmaceutical compositions |
JPH01180878A (ja) * | 1988-01-11 | 1989-07-18 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピラゾール化合物 |
EP0328200A1 (en) * | 1988-02-12 | 1989-08-16 | Merck Sharp & Dohme Ltd. | Five-membered ring systems with bonded azacyclic ring substituents |
WO1989010924A1 (en) * | 1988-05-12 | 1989-11-16 | National Research Development Corporation | Indazole derivatives |
JPH03167175A (ja) * | 1989-09-11 | 1991-07-19 | Hoechst Roussel Pharmaceut Inc | 3‐(1‐置換‐4‐ピペラジニル)‐1h‐インダゾール |
EP0475352A1 (en) * | 1990-09-10 | 1992-03-18 | Hoechst-Roussel Pharmaceuticals Incorporated | 3-(1H-Indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments |
JPH06206872A (ja) * | 1992-10-06 | 1994-07-26 | Yoshitomi Pharmaceut Ind Ltd | 縮合型ピラゾール化合物 |
WO1997003069A1 (en) * | 1995-07-13 | 1997-01-30 | Glaxo Group Limited | Heterocyclic compounds and pharmaceutical compositions containing them |
WO1997023480A1 (en) * | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
WO1999023077A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
WO2000000490A2 (en) * | 1998-06-26 | 2000-01-06 | Eli Lilly And Company | 5-ht1f agonists |
WO2000000487A1 (en) * | 1998-06-30 | 2000-01-06 | Eli Lilly And Company | 5-ht1f agonists |
WO2000006173A1 (en) * | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | 5-ht1f agonists |
WO2000021959A1 (en) * | 1998-10-09 | 2000-04-20 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
JP2000198734A (ja) * | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
WO2000075118A1 (en) * | 1999-06-03 | 2000-12-14 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) |
WO2001012621A1 (en) * | 1999-08-13 | 2001-02-22 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
WO2001019833A1 (en) * | 1999-09-14 | 2001-03-22 | Aventis Pharmaceuticals, Inc. | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists |
WO2001053268A2 (en) * | 2000-01-18 | 2001-07-26 | Agouron Pharmaceuticals, Inc. | Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
WO2001057024A1 (en) * | 2000-02-04 | 2001-08-09 | University College London | Blockade of voltage dependent sodium channels |
WO2001064674A1 (en) * | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
WO2002010137A2 (en) * | 2000-07-31 | 2002-02-07 | Signal Pharmaceuticals, Inc. | Indazole derivatives as jnk inhibitors |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760028A (en) * | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
SI0912558T1 (en) * | 1996-06-25 | 2003-10-31 | Pfizer Inc. | Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors |
DE19821002A1 (de) * | 1998-05-11 | 1999-11-18 | Dresden Arzneimittel | Neue 1,5- und 3-O-substituierte 1H-Indazole mit antiasthmatischer, antiallergischer, entzündungshemmender, immunmodulierender und neuroprotektiver Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2000000491A1 (en) | 1998-06-29 | 2000-01-06 | The Regents Of The University Of California | Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents |
BR9916223A (pt) | 1998-12-17 | 2001-09-04 | Hoffmann La Roche | 4-ariloxindóis como inibidores de cinases de proteìna jnk |
DE69938258T2 (de) | 1998-12-17 | 2009-02-26 | F. Hoffmann-La Roche Ag | 4,5-pyrazinoxindole als proteinkinasehemmer |
CN1147486C (zh) | 1998-12-17 | 2004-04-28 | 霍夫曼-拉罗奇有限公司 | 4-和5-炔基羟吲哚和4-和5-烯基羟吲哚 |
DE60041763D1 (de) | 1999-04-23 | 2009-04-23 | Vertex Pharma | Inhibitoren von c-jun n-terminal kinasen (jnk) |
CA2383268A1 (en) | 1999-08-19 | 2001-02-22 | Signal Pharmaceuticals, Inc. | Pyrazoloanthrone and derivatives thereof as jnk inhibitors and their compositions |
EP1088822A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl hydrazide derivatives |
EP1088815A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
EP1088821A1 (en) | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonamide derivatives |
EP1110957A1 (en) | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivatives and their use as JNK modulators |
US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
CN1300116C (zh) * | 2001-04-16 | 2007-02-14 | 卫材株式会社 | 1h-吲唑化合物 |
-
2002
- 2002-04-15 CN CNB028082907A patent/CN1300116C/zh not_active Expired - Fee Related
- 2002-04-15 EP EP02724612A patent/EP1380576B1/en not_active Expired - Lifetime
- 2002-04-15 JP JP2002581404A patent/JP4535680B2/ja not_active Expired - Fee Related
- 2002-04-15 DE DE60234510T patent/DE60234510D1/de not_active Expired - Lifetime
- 2002-04-15 KR KR10-2003-7013494A patent/KR20040007497A/ko not_active Application Discontinuation
- 2002-04-15 US US10/469,399 patent/US6982274B2/en not_active Expired - Fee Related
- 2002-04-15 WO PCT/JP2002/003735 patent/WO2002083648A1/ja active Application Filing
- 2002-04-15 AT AT02724612T patent/ATE449763T1/de not_active IP Right Cessation
- 2002-04-15 CA CA002440842A patent/CA2440842A1/en not_active Abandoned
- 2002-04-15 AU AU2002255263A patent/AU2002255263B2/en not_active Ceased
-
2005
- 2005-08-12 US US11/202,234 patent/US7541376B2/en not_active Expired - Fee Related
-
2009
- 2009-04-20 US US12/426,818 patent/US7776890B2/en not_active Expired - Fee Related
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1266763B (de) * | 1965-07-27 | 1968-04-25 | Kalle Ag | Verfahren zur Herstellung von in 3-Stellung substituierten Indol- und Indazolderivaten |
JPS51125281A (en) * | 1975-01-15 | 1976-11-01 | Chugai Pharmaceut Co Ltd | A process for preparing indazole derivatives |
JPS52122366A (en) * | 1976-04-02 | 1977-10-14 | Chugai Pharmaceut Co Ltd | Indazole derivatives |
EP0023633A1 (en) * | 1979-07-16 | 1981-02-11 | Chugai Seiyaku Kabushiki Kaisha | Pyrazoloindazole derivatives and process for preparing the same and pharmaceutical compositions |
JPH01180878A (ja) * | 1988-01-11 | 1989-07-18 | Yoshitomi Pharmaceut Ind Ltd | 縮合ピラゾール化合物 |
EP0328200A1 (en) * | 1988-02-12 | 1989-08-16 | Merck Sharp & Dohme Ltd. | Five-membered ring systems with bonded azacyclic ring substituents |
WO1989010924A1 (en) * | 1988-05-12 | 1989-11-16 | National Research Development Corporation | Indazole derivatives |
JPH03167175A (ja) * | 1989-09-11 | 1991-07-19 | Hoechst Roussel Pharmaceut Inc | 3‐(1‐置換‐4‐ピペラジニル)‐1h‐インダゾール |
EP0475352A1 (en) * | 1990-09-10 | 1992-03-18 | Hoechst-Roussel Pharmaceuticals Incorporated | 3-(1H-Indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments |
JPH06206872A (ja) * | 1992-10-06 | 1994-07-26 | Yoshitomi Pharmaceut Ind Ltd | 縮合型ピラゾール化合物 |
WO1997003069A1 (en) * | 1995-07-13 | 1997-01-30 | Glaxo Group Limited | Heterocyclic compounds and pharmaceutical compositions containing them |
WO1997023480A1 (en) * | 1995-12-22 | 1997-07-03 | The Du Pont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
WO1999023077A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
WO2000000490A2 (en) * | 1998-06-26 | 2000-01-06 | Eli Lilly And Company | 5-ht1f agonists |
WO2000000487A1 (en) * | 1998-06-30 | 2000-01-06 | Eli Lilly And Company | 5-ht1f agonists |
WO2000006173A1 (en) * | 1998-07-31 | 2000-02-10 | Eli Lilly And Company | 5-ht1f agonists |
WO2000021959A1 (en) * | 1998-10-09 | 2000-04-20 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
JP2000198734A (ja) * | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
WO2000075118A1 (en) * | 1999-06-03 | 2000-12-14 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) |
WO2001012621A1 (en) * | 1999-08-13 | 2001-02-22 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
WO2001019833A1 (en) * | 1999-09-14 | 2001-03-22 | Aventis Pharmaceuticals, Inc. | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as d4 antagonists |
WO2001053268A2 (en) * | 2000-01-18 | 2001-07-26 | Agouron Pharmaceuticals, Inc. | Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation |
WO2001057024A1 (en) * | 2000-02-04 | 2001-08-09 | University College London | Blockade of voltage dependent sodium channels |
WO2001064674A1 (en) * | 2000-03-01 | 2001-09-07 | Janssen Pharmaceutica N.V. | 2,4-disubstituted thiazolyl derivatives |
WO2002010137A2 (en) * | 2000-07-31 | 2002-02-07 | Signal Pharmaceuticals, Inc. | Indazole derivatives as jnk inhibitors |
Non-Patent Citations (14)
Title |
---|
BERGMAN J. ET AL: "Synthesis of gem-dinitro heterocyclic compounds, their ring-opening reactions and transformation into indoles, indazoles and benzoxazinones", TETRAHEDRON, vol. 55, 1999, pages 10447 - 10466, XP002953898 * |
BOEHM H.-J. ET AL: "A novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening", J. MED. CHEM., vol. 43, 2000, pages 2664 - 2674, XP002953890 * |
CAVA M.P. ET AL: "A novel pschorr reaction in the papaverine series", J. ORG. CHEM., vol. 38, no. 13, 1973, pages 2394 - 2397, XP002953889 * |
JONES W.D. JR. ET AL: "The traction of 4-alkyl-3-thiosemicarbazides with beta-haloketones", J. HETEROCYCLIC CHEM., vol. 20, 1983, pages 1359 - 1361, XP002953886 * |
KAWAKUBO H. ET AL: "3-Aminoindazole yudotai no kouensho, chintsu oyobi genetsu sayo", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 107, no. 1, 1987, pages 28 - 36, XP002953887 * |
KAWAKUBO H. ET AL: "Studies on 3-aminoindazoles. I. Synthesis of 1- or 3-(substituted 3-amino) indazoles", CHEM. PHARM. BULL., vol. 35, no. 6, 1987, pages 2292 - 2299, XP002953888 * |
MOHIT A.A. ET AL: "P49(3F12) Kinase: A novel MAP kinase expressed in a subset of neurons in the human nervous system", NEURON, vol. 14, 1995, pages 67 - 78, XP002953893 * |
PATEL M. ET AL: "Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents", BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 3217 - 3220, XP002953885 * |
WRZECIONO U. ET AL: "Azoles, Part 14: On the behaviour of 5-chloro-2-nitroindazole against aliphatic and cyclic amines", PHARMAZIE, vol. 40, no. 2, 1985, pages 105 - 108, XP002953897 * |
WRZECIONO U. ET AL: "Azoles, Part 33: 5-Fluoro-indazole derivatives", PHARMAZIE, vol. 47, no. 1, 1992, pages 105 - 108, XP002953896 * |
WRZECIONO U. ET AL: "Synthesis and anti-inflammatory activity of some indazole derivatives. Part 36: Azoles", PHARMAZIE, vol. 48, no. 8, 1993, pages 582 - 584, XP002953895 * |
YASUO FUJIMURA ET AL: "2, 3-dihydro-1H-pyrazolo(1,2-a)indazolium yudotai no gosei to yakuri kassei ni tsuite", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 106, no. 11, 1986, pages 1002 - 1007, XP002953891 * |
YASUO FUJIMURA ET AL: "3-Phenylindazole yudotai no gosei to yakuri kassei ni tsuite", JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 106, no. 11, 1986, pages 995 - 1001, XP002953892 * |
ZHU X. ET AL: "Activation and redistribution of c-Jun N-terminal kinase/sterss activated protein kinase in degenerating neurons in Alzheimer's disease", J. NEUROCHEM., vol. 76, 2001, pages 435 - 441, XP002953894 * |
Cited By (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003064397A1 (en) * | 2002-01-25 | 2003-08-07 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
US7041687B2 (en) | 2002-01-25 | 2006-05-09 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
EP2295412A1 (en) * | 2002-01-25 | 2011-03-16 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
EP2295413A1 (en) * | 2002-01-25 | 2011-03-16 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
WO2003068754A1 (en) * | 2002-02-13 | 2003-08-21 | Astrazeneca Ab | Therapeutic substituted indazole derivatives |
US7390797B2 (en) | 2002-02-28 | 2008-06-24 | Eisai Co., Ltd. | Fused indazole compounds |
US7473701B2 (en) | 2002-03-11 | 2009-01-06 | Aventis Pharma S.A. | Substituted indazoles, compositions containing them, method of production and use |
JP2005533004A (ja) * | 2002-03-11 | 2005-11-04 | アベンティス・ファーマ・ソシエテ・アノニム | 抗癌活性を有する置換インダゾール |
JP4643910B2 (ja) * | 2002-03-11 | 2011-03-02 | アベンティス・ファーマ・ソシエテ・アノニム | 抗癌活性を有する置換インダゾール |
WO2003101968A1 (fr) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Compose de pyrazole et composition medicinale le contenant |
US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
US7186716B2 (en) | 2002-08-12 | 2007-03-06 | Sugen, Inc. | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
US7241791B2 (en) | 2002-09-25 | 2007-07-10 | Wyeth | Substituted 4-(indazol-3-yl)phenols |
WO2004031159A1 (en) * | 2002-09-25 | 2004-04-15 | Wyeth | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (er) ligands and their use in the treatment of inflammatory diseases |
CN1321984C (zh) * | 2002-09-25 | 2007-06-20 | 惠氏公司 | 作为雌激素受体(er)配体的取代的4-(吲唑-3-基)苯酚及其在治疗炎症中的应用 |
JP2006512143A (ja) * | 2002-12-31 | 2006-04-13 | セルジーン・コーポレーション | 薬剤被覆ステントおよびその使用方法 |
WO2004089366A1 (en) * | 2003-04-10 | 2004-10-21 | Pfizer Japan, Inc. | Bicyclic compounds as nr2b receptor antagonists |
EP1633740A2 (en) * | 2003-06-19 | 2006-03-15 | SmithKline Beecham Corporation | Chemical compounds |
JP2007516173A (ja) * | 2003-06-19 | 2007-06-21 | スミスクライン ビーチャム コーポレーション | 化合物 |
JP4869068B2 (ja) * | 2003-06-19 | 2012-02-01 | スミスクライン ビーチャム コーポレーション | 化合物 |
US7560467B2 (en) | 2003-06-19 | 2009-07-14 | Smithkline Beecham Corporation | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors |
EP1633740A4 (en) * | 2003-06-19 | 2008-11-19 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
WO2004113303A1 (en) * | 2003-06-26 | 2004-12-29 | Astrazeneca Ab | INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF |
JP2005075834A (ja) * | 2003-09-03 | 2005-03-24 | Carlsbad Technology Inc | 神経変性疾患の処置 |
US8642779B2 (en) | 2003-09-23 | 2014-02-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7652135B2 (en) | 2003-09-23 | 2010-01-26 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
WO2005035516A1 (ja) * | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
JP2007511618A (ja) * | 2003-11-19 | 2007-05-10 | シグナル ファーマシューティカルズ,エルエルシー | インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法 |
WO2005066136A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
US7544707B2 (en) | 2003-12-22 | 2009-06-09 | Eli Lilly And Company | Bicyclic derivatives as PPAR modulators |
US7378532B2 (en) | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
US8268994B2 (en) | 2004-07-27 | 2012-09-18 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
JP2008508304A (ja) * | 2004-07-27 | 2008-03-21 | エスジーエックス ファーマシューティカルズ、インコーポレイテッド | 縮合環ヘテロ環キナーゼ調節因子 |
US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
US7803824B2 (en) | 2004-10-29 | 2010-09-28 | Alcon, Inc. | Use of inhibitors of Jun N-terminal kinases to treat glaucoma |
EP2248521A1 (en) | 2004-10-29 | 2010-11-10 | Alcon, Inc. | Inhibitors of jun n-terminal kinases for treating glaucomatous retinopathy and ocular diseases |
JP2008530028A (ja) * | 2005-02-24 | 2008-08-07 | テバ ファーマシューティカル インダストリーズ リミティド | リネゾリッド中間体の調製方法 |
WO2008001885A1 (fr) | 2006-06-30 | 2008-01-03 | Kyowa Hakko Kirin Co., Ltd. | INHIBITEUR DE KINASE Abl |
WO2008001886A1 (fr) | 2006-06-30 | 2008-01-03 | Kyowa Hakko Kirin Co., Ltd. | Inhibiteur d'aurora |
US8722903B2 (en) | 2006-07-01 | 2014-05-13 | Merck Patent Gmbh | Indazole derivatives for the treatment of HSP9O-induced diseases |
JP2009541377A (ja) * | 2006-07-01 | 2009-11-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hsp90誘発疾患を治療するためのインダゾール誘導体 |
WO2008111441A1 (ja) | 2007-03-05 | 2008-09-18 | Kyowa Hakko Kirin Co., Ltd. | 医薬組成物 |
DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
DE102007032739A1 (de) | 2007-07-13 | 2009-01-15 | Merck Patent Gmbh | Chinazolinamidderivate |
JP2010536846A (ja) * | 2007-08-17 | 2010-12-02 | エルジー・ライフ・サイエンシーズ・リミテッド | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 |
DE102007041116A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-Dihydro-isoindolderivate |
JP2011515414A (ja) * | 2008-03-20 | 2011-05-19 | アボット・ラボラトリーズ | Trpv1アンタゴニストである中枢神経系薬剤を作製する方法 |
DE102008061214A1 (de) | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
JP2012521429A (ja) * | 2009-03-23 | 2012-09-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛治療用のp2x3受容体アンタゴニスト |
DE102009054302A1 (de) | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
WO2011060873A1 (de) | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
DE102010046837A1 (de) | 2010-09-29 | 2012-03-29 | Merck Patent Gmbh | Phenylchinazolinderivate |
WO2012041435A1 (de) | 2010-09-29 | 2012-04-05 | Merck Patent Gmbh | Phenylchinazolinderivate |
US11840534B2 (en) | 2012-06-13 | 2023-12-12 | Incyte Corporation | Substituted tricyclic compounds as FGFR inhibitors |
US9688654B2 (en) | 2013-03-04 | 2017-06-27 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
WO2014134774A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9493440B2 (en) | 2013-03-04 | 2016-11-15 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9416126B2 (en) | 2013-03-04 | 2016-08-16 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US9440952B2 (en) | 2013-03-04 | 2016-09-13 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
US11530214B2 (en) | 2013-04-19 | 2022-12-20 | Incyte Holdings Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11667635B2 (en) | 2015-02-20 | 2023-06-06 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
JP2020516632A (ja) * | 2017-04-11 | 2020-06-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | フッ素置換されたインダゾール化合物及びその使用 |
JP7090639B2 (ja) | 2017-04-11 | 2022-06-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | フッ素置換されたインダゾール化合物及びその使用 |
US11472801B2 (en) | 2017-05-26 | 2022-10-18 | Incyte Corporation | Crystalline forms of a FGFR inhibitor and processes for preparing the same |
US11524968B2 (en) | 2017-10-18 | 2022-12-13 | Hk Inno.N Corporation | Heterocyclic compound as a protein kinase inhibitor |
US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
US12024517B2 (en) | 2018-05-04 | 2024-07-02 | Incyte Corporation | Salts of an FGFR inhibitor |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
JP2022508128A (ja) * | 2018-11-15 | 2022-01-19 | エイチケー イノ.エヌ コーポレーション | タンパク質キナーゼ阻害剤としての新規化合物およびそれを含む薬学的組成物 |
JP7312823B2 (ja) | 2018-11-15 | 2023-07-21 | エイチケー イノ.エヌ コーポレーション | タンパク質キナーゼ阻害剤としての新規化合物およびそれを含む薬学的組成物 |
US11702421B2 (en) | 2018-12-31 | 2023-07-18 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11084825B2 (en) | 2018-12-31 | 2021-08-10 | Biomea Fusion, Llc | Substituted pyridines as irreversible inhibitors of menin-MLL interaction |
US11845753B2 (en) | 2018-12-31 | 2023-12-19 | Biomea Fusion, Inc. | Inhibitors of menin-mll interaction |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11607416B2 (en) | 2019-10-14 | 2023-03-21 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
US12018032B2 (en) | 2021-08-20 | 2024-06-25 | Biomea Fusion, Inc. | Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction |
CN113999211A (zh) * | 2021-11-23 | 2022-02-01 | 郑州大学 | 一类特异性抗前列腺癌活性的含1,2,3-三氮唑的吲唑骨架衍生物 |
US12071428B2 (en) | 2024-02-22 | 2024-08-27 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
US7541376B2 (en) | 2009-06-02 |
EP1380576A1 (en) | 2004-01-14 |
CN1300116C (zh) | 2007-02-14 |
JPWO2002083648A1 (ja) | 2004-08-05 |
US6982274B2 (en) | 2006-01-03 |
AU2002255263B2 (en) | 2006-12-14 |
JP4535680B2 (ja) | 2010-09-01 |
ATE449763T1 (de) | 2009-12-15 |
US7776890B2 (en) | 2010-08-17 |
EP1380576B1 (en) | 2009-11-25 |
US20090203691A1 (en) | 2009-08-13 |
CA2440842A1 (en) | 2002-10-24 |
DE60234510D1 (de) | 2010-01-07 |
US20040127538A1 (en) | 2004-07-01 |
EP1380576A4 (en) | 2005-02-16 |
US20050282880A1 (en) | 2005-12-22 |
CN1512987A (zh) | 2004-07-14 |
KR20040007497A (ko) | 2004-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002083648A1 (en) | Novel 1h-indazole compound | |
WO2002032872A8 (en) | Nitrogenous aromatic ring compounds | |
EP1302462A4 (en) | Sulphonic derivatives, process for their preparation and their use | |
WO2002062800A1 (fr) | Composé cyclique fondu azoté bicyclique | |
MXPA03006918A (es) | Compuestos heterociclicos fusionados. | |
EP1283039A4 (en) | INHIBITORS OF -SECRETASE | |
WO2004014860A3 (en) | Fused heterocyclic compounds as peptidase inhibitors | |
WO1999042456A3 (en) | Novel compounds and their use as positive ampa receptor modulators | |
WO2001014376A8 (en) | Novel spiro compounds | |
PH12009500610A1 (en) | 4-imidazolin-2-one compounds | |
EP0738716A3 (en) | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides | |
AU9022901A (en) | Pyridazinones and triazinones and medicinal use thereof | |
DE60039183D1 (de) | Verbindungen mit antibakteriellen und antiparasitischen eigenschaften | |
WO2003042203A1 (fr) | Compose de chrome | |
EP1333029A4 (en) | D RIV S OF PYRIMIDINE AND HERBICIDES CONTAINING THEM | |
EP1538184A4 (en) | RESIN COMPOSITION | |
DE60239170D1 (de) | Bicyclische Verbindungen | |
WO2003029218A1 (fr) | Compose azote et utilisation correspondante | |
AR026720A1 (es) | Compuestos uracilo y aplicacion de los mismos. | |
EP1466904A4 (en) | BIARYL CONNECTION AND ITS USE | |
EP1544194A4 (en) | DERIVATIVE 4- (ARYL SUBSTITUTED) -5-HYDROXYISOQUINOLINONE | |
ATE544185T1 (de) | Konjugiertes copolymer enthaltend triazin, seine herstellung und verwendung | |
CA2244417A1 (en) | Optically active bisoxazoline compounds, production and use thereof | |
EP1026162A4 (en) | ANTI-RHUMATISMAL AGENT | |
EP1310490A4 (en) | GPR14 ANTAGONIST |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002581404 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002255263 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10469399 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2440842 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002724612 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028082907 Country of ref document: CN Ref document number: 1020037013494 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2002724612 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |